


**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions of the claims and listing of the claims in the application:

What is claimed is:

1. (Withdrawn) A method of treating a patient suffering from or susceptible to an RSV infection, which method comprises administering to said patient an effective amount of a benzodiazepine derivative of formula (I), or a pharmaceutically acceptable salt thereof,



wherein:

- $R^1$  represents  $C_{1-6}$  alkyl, aryl or heteroaryl;
- $R^2$  represents hydrogen or  $C_{1-6}$  alkyl;
- each  $R^3$  is the same or different and represents halogen, hydroxy,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy,  $C_{1-6}$  alkylthio,  $C_{1-6}$  haloalkyl,  $C_{1-6}$  haloalkoxy, amino, mono( $C_{1-6}$  alkyl)amino, di( $C_{1-6}$  alkyl)amino, nitro, cyano,  $-CO_2R'$ ,  $-CONR'R''$ ,  $-NH-CO-R'$ ,  $-S(O)R'$ ,  $-S(O)_2R'$ ,  $-NH-S(O)_2R'$ ,  $-S(O)NR'R''$  or  $-S(O)_2NR'R''$ , wherein each  $R'$  and  $R''$  is the same or different and represents hydrogen or  $C_{1-6}$  alkyl;
- $n$  is from 0 to 3;
- $R^4$  represents hydrogen or  $C_{1-6}$  alkyl;
- $R^5$  represents  $C_{1-6}$  alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-( $C_{1-6}$  alkyl)-, heteroaryl-( $C_{1-6}$  alkyl)-, carbocyclyl-( $C_{1-6}$  alkyl)-, heterocyclyl-( $C_{1-6}$  alkyl)-, aryl-( $C_{1-6}$  hydroxyalkyl)-, heteroaryl-( $C_{1-6}$  hydroxyalkyl)-, carbocyclyl-( $C_{1-6}$  hydroxyalkyl)-, heterocyclyl-( $C_{1-6}$  hydroxyalkyl)-, aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)-, carbocyclyl-C(O)-C(O)-, heterocyclyl-C(O)-C(O)- or  $-XR^6$ ;
- $X$  represents  $-CO-$ ,  $-S(O)-$  or  $-S(O)_2-$ ; and
- $R^6$  represents  $C_{1-6}$  alkyl, hydroxy,  $C_{1-6}$  alkoxy,  $C_{1-6}$  alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-( $C_{1-6}$  alkyl)-, heteroaryl-( $C_{1-6}$  alkyl)-, carbocyclyl-( $C_{1-6}$

alkyl)-, heterocyclyl-(C<sub>1-6</sub> alkyl)-, aryl-(C<sub>1-6</sub> alkyl)-O-, heteroaryl-(C<sub>1-6</sub> alkyl)-O-, carbocyclyl-(C<sub>1-6</sub> alkyl)-O-, heterocyclyl-(C<sub>1-6</sub> alkyl)-O- or -NR'<sup>1</sup>R'' wherein each R' and R'' is the same or different and represents hydrogen, C<sub>1-6</sub> alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C<sub>1-6</sub> alkyl)-, heteroaryl-(C<sub>1-6</sub> alkyl)-, carbocyclyl-(C<sub>1-6</sub> alkyl)- or heterocyclyl-(C<sub>1-6</sub> alkyl)-.

2. (Withdrawn) A method according to claim 1 wherein:

- each R<sup>3</sup> is the same or different and represents halogen, hydroxy, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> haloalkoxy, amino, mono(C<sub>1-6</sub> alkyl)amino, di(C<sub>1-6</sub> alkyl)amino, nitro, cyano, -CO<sub>2</sub>R', -CONR'<sup>1</sup>R'', -NH-CO-R', -S(O)R', -S(O)<sub>2</sub>R', -NH-S(O)<sub>2</sub>R' or -S(O)NR'<sup>1</sup>R'', wherein each R' and R'' is the same or different and represents hydrogen or C<sub>1-6</sub> alkyl;
- R<sup>5</sup> represents C<sub>1-6</sub> alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C<sub>1-6</sub> alkyl)-, heteroaryl-(C<sub>1-6</sub> alkyl)-, carbocyclyl-(C<sub>1-6</sub> alkyl)-, heterocyclyl-(C<sub>1-6</sub> alkyl)- or -XR<sup>6</sup>;
- X represents -CO-, -S(O)- or -S(O)<sub>2</sub>-; and
- R<sup>6</sup> represents C<sub>1-6</sub> alkyl, hydroxy, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C<sub>1-6</sub> alkyl)-, heteroaryl-(C<sub>1-6</sub> alkyl)-, carbocyclyl-(C<sub>1-6</sub> alkyl)-, heterocyclyl-(C<sub>1-6</sub> alkyl)- or -NR'<sup>1</sup>R'' wherein each R' and R'' is the same or different and represents hydrogen, C<sub>1-6</sub> alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C<sub>1-6</sub> alkyl)- or heteroaryl-(C<sub>1-6</sub> alkyl)-.

3. (Withdrawn) A method according to claim 1, wherein R<sup>1</sup> is C<sub>1-2</sub> alkyl or aryl.


4. (Withdrawn) A method according to claim 1, wherein R<sup>2</sup> is hydrogen.

5. (Withdrawn) A method according to claim 1, wherein R<sup>3</sup> is halogen, hydroxy, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylthio, C<sub>1-4</sub> haloalkyl, C<sub>1-4</sub> haloalkoxy, amino, mono(C<sub>1-4</sub> alkyl)amino or di(C<sub>1-4</sub> alkyl)amino.

6. (Withdrawn) A method according to claim 5, wherein R<sup>3</sup> is fluorine, chlorine, bromine, C<sub>1-2</sub> alkyl, C<sub>1-2</sub> alkoxy, C<sub>1-2</sub> alkylthio, C<sub>1-2</sub> haloalkyl, C<sub>1-2</sub> haloalkoxy, amino, mono(C<sub>1-2</sub> alkyl)amino or di (C<sub>1-2</sub> alkyl)amino.

7. (Withdrawn) A method according to claim 1, wherein  $R^4$  is hydrogen or  $C_{1-2}$  alkyl.
8. (Withdrawn) A method according to claim 1, wherein  $R^5$  is  $C_{1-6}$  alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-( $C_{1-4}$  alkyl)-, heteroaryl-( $C_{1-4}$  alkyl)-, carbocyclyl-( $C_{1-4}$  alkyl)-, heterocyclyl-( $C_{1-4}$  alkyl)-, aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)- or  $-XR^6$ .
9. (Withdrawn) A method according to claim 8, wherein  $R^5$  is  $C_{1-4}$  alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, phenyl-( $C_{1-2}$  alkyl)-, heteroaryl-( $C_{1-2}$  alkyl)-, phenyl-C(O)-C(O)-, heteroaryl-C(O)-C(O)- or  $-XR^6$ .
10. (Withdrawn) A method according to claim 9, wherein  $R^5$  is  $C_{1-4}$  alkyl, phenyl, thienyl, furanyl, isoxazolyl, pyridyl, cyclopentyl, cyclohexyl, benzothienyl, dihydrobenzofuranyl, phenyl- $CH_2$ -, furanyl- $CH_2$ -, phenyl-C(O)-C(O)-, thienyl-C(O)-C(O)- or  $-XR^6$ .
11. (Withdrawn) A method according to claim 1 wherein X is  $-CO-$  or  $-S(O)_2-$ .
12. (Withdrawn) A method according to claim 1 wherein, when  $R^6$  is a group  $-NR'R''$  wherein each  $R'$  and  $R''$  is the same or different and represents hydrogen,  $C_{1-4}$  alkyl, aryl, carbocyclyl, heterocyclyl, aryl-( $C_{1-4}$  alkyl)- or heteroaryl-( $C_{1-4}$  alkyl)-.
13. (Withdrawn) A method according to claim 12, wherein when  $R^6$  is a group  $-NR'R''$  each  $R'$  and  $R''$  is the same or different and represents hydrogen,  $C_{1-4}$  alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl- $CH_2$ -.
14. (Withdrawn) A method according to claim 13, wherein when  $R^6$  is a group  $-NR'R''$  and one of  $R'$  and  $R''$  is hydrogen.
15. (Withdrawn) A method according to claim 1 wherein  $R^6$  is  $C_{1-6}$  alkyl, hydroxy,  $C_{1-6}$  alkoxy,  $C_{1-6}$  alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-( $C_{1-4}$  alkyl)-, heteroaryl-( $C_{1-4}$  alkyl)-, carbocyclyl-( $C_{1-4}$  alkyl)-, heterocyclyl-( $C_{1-4}$  alkyl)-, aryl-( $C_{1-4}$  hydroxyalkyl)-, heteroaryl-( $C_{1-4}$  hydroxyalkyl)-, carbocyclyl-( $C_{1-4}$  hydroxyalkyl)-, heterocyclyl-( $C_{1-4}$  hydroxyalkyl)-, aryl-( $C_{1-4}$  alkyl)-O-, heteroaryl-( $C_{1-4}$  alkyl)-O-, carbocyclyl-( $C_{1-4}$  alkyl)-O-, heterocyclyl-( $C_{1-4}$  alkyl)-O- or  $-NR'R''$ .

16. (Withdrawn) A method according to claim 15, wherein  $R^6$  is  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy,  $C_{1-6}$  alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, phenyl- $(C_{1-2}$  alkyl)-, phenyl- $(C_{1-2}$  alkyl)-O-, heteroaryl- $(C_{1-2}$  alkyl)-, phenyl- $(C_{1-2}$  hydroxyalkyl)-, heteroaryl- $(C_{1-2}$  hydroxyalkyl)- or  $-NR'R''$ .
17. (Withdrawn) A method according to claim 16, wherein  $R^6$  is  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidinyl, morpholinyl, phenyl- $(C_{1-2}$  alkyl)-, phenyl- $CH_2-CH(OH)-$ , phenyl- $CH(OH)-CH_2-$ , phenyl- $(C_{1-2}$  alkyl)-O-, 1H-benzo[d]imidazol-2(3H)-onyl or  $-NR'R''$ .
18. (Withdrawn) A method according to claim 1, wherein the benzodiazepine derivative of formula (I) is a benzodiazepine derivative of formula (Ia):



wherein:

- $R^1$  is phenyl or methyl;
- $R^3$  is methyl or chlorine;
- $n$  is 0 or 1;
- $R^4$  is hydrogen or methyl;
- $R^5$  is phenyl- $CH_2-$ , furanyl- $CH_2-$ , thienyl- $C(O)-C(O)-$  or  $-XR^6$ ;
- $X$  is  $-CO-$  or  $-S(O)_2-$ ; and
- $R^6$  is  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidinyl, morpholinyl, phenyl- $(C_{1-2}$  alkyl)-, phenyl- $CH_2-CH(OH)-$ , phenyl- $CH(OH)-CH_2-$ , phenyl- $(C_{1-2}$  alkyl)-O-, 1H-benzo[d]imidazol-2(3H)-onyl or  $-NR'R''$  wherein each

$R'$  and  $R''$  is the same or different and represents hydrogen,  $C_{1-4}$  alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl-( $CH_2$ )-,

the phenyl moiety in the group  $R^1$  being unsubstituted or substituted by a single fluorine, chlorine,  $C_{1-2}$  alkyl,  $C_{1-2}$  alkoxy,  $C_{1-2}$  alkylthio,  $C_{1-2}$  haloalkyl or  $C_{1-2}$  haloalkoxy substituent;


the aryl moieties in the groups  $R^5$  and  $R^6$  being unsubstituted or substituted by 1,2 or 3 substituents selected from fluorine, chlorine, bromine, iodine,  $C_{1-4}$  alkyl,  $C_{2-4}$  acyl, hydroxy,  $C_{1-4}$  alkoxy,  $C_{1-4}$  alkylthio,  $C_{1-4}$  haloalkyl,  $C_{1-4}$  haloalkoxy, amino, mono( $C_{1-4}$  alkyl)amino, di( $C_{1-4}$  alkyl)amino, nitro,  $-CO_2R'$ ,  $-S(O)_2R'$  and  $-S(O)_2NH_2$ , wherein  $R'$  represents  $C_{1-2}$  alkyl;

the heteroaryl moieties in the groups  $R^5$  and  $R^6$  being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine,  $C_{1-2}$  alkyl,  $C_{1-2}$  haloalkyl and di( $C_{1-2}$  alkyl)amino; and

the heterocyclyl and carbocyclyl moieties in the  $R^6$  group being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy,  $C_{1-4}$  haloalkyl and nitro.

19. (Withdrawn) A method according to claim 1, wherein the patient is a child under two years of age.
20. (Withdrawn) A method according to claim 19 wherein said child suffers from chronic lung disease.
21. (Withdrawn) A method according to claim 1 wherein the patient is an infant less than six years of age who was born after 32 weeks of gestation or less.
22. (Withdrawn) A method according to claim 1, wherein the benzodiazepine derivative or salt thereof is administered intranasally or intrabronchially.
23. (Withdrawn) A method according to claim 1, wherein an anti-inflammatory compound or an anti-influenza compound is further administered to the patient.
24. (Withdrawn) A method according to claim 23 wherein the anti-inflammatory compound is budesonide or fluticasone.

25. (Withdrawn) A method according to claim 23 wherein the anti-inflammatory compound is a leukotriene antagonist, phosphodiesterase 4 inhibitor or TNF alpha inhibitor.
26. (Withdrawn) A method according to claim 23 wherein the anti-inflammatory compound is an interleukin 8 or interleukin 9 inhibitor.
- 27-30. (Canceled)
31. (Withdrawn) An inhaler or nebuliser containing a medicament which comprises
- (a) a benzodiazepine derivative of formula (I), as defined in claim 1, or a pharmaceutically acceptable salt thereof, and
  - (b) a pharmaceutically acceptable carrier or diluent.
32. (Withdrawn) A product comprising a compound of formula (I), or pharmaceutically acceptable salt thereof, as defined in claim 1, and an anti-inflammatory compound, or an anti-influenza compound.
33. (Withdrawn) A method of treating a patient suffering from or susceptible to concomitant RSV and influenza infections, which method comprises administering to said patient an effective amount of a product according to claim 32.
34. (Withdrawn) A method of treating a patient suffering from or susceptible to human metapneumovirus, measles, parainfluenza viruses, mumps, yellow fever virus (B5 strain), Dengue 2 virus or West Nile virus, which method comprises administering to said patient an effective amount of a compound of formula (I), as defined in claim 1, or a pharmaceutically acceptable salt thereof.
- 35-37. (Canceled)
38. (Currently amended) A compound of formula (Ic), or a pharmaceutically acceptable salt thereof,



wherein:

- $R^1$  is phenyl or methyl;
- $R^3$  is methyl or chlorine;
- $n$  is 0 or 1;
- $R^4$  is hydrogen or methyl;
- $R^{5'}$  is ~~phenyl-CH<sub>2</sub>-thienyl~~ C(O)-C(O)- or -X';
- X' is ~~CO-R<sup>6'</sup>~~, ~~CONR'R''~~, ~~S(O)<sub>2</sub>R<sup>6'''</sup>~~ or ~~S(O)<sub>2</sub>NR<sub>4</sub>R<sub>5</sub>~~; and
- $R^{6'}$  is ~~C<sub>1-4</sub>-alkoxy, benzodioxinyl, 9H fluoren-9-onyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, cyclopentyl, piperazinyl, piperidinyl, morpholinyl, phenyl-CH<sub>2</sub>-CH(OH)-, phenyl-CH(OH)-CH<sub>2</sub>-, phenyl-(C<sub>2</sub>-alkyl)-O- or 1H-benzo[d]imidazol-2(3H)-only;~~
- $R^{6'''}$  is ~~C<sub>1-4</sub>-alkyl, C<sub>1-4</sub>-alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H fluoren-9-onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidinyl, morpholinyl, phenyl-(C<sub>1-2</sub>-alkyl)-, phenyl-CH<sub>2</sub>-CH(OH)-, phenyl-CH(OH)-CH<sub>2</sub>-, phenyl-(C<sub>1-2</sub>-alkyl)-O- or 1H-benzo[d]imidazol-2(3H)-only;~~
- each  $R'$  and  $R''$  is the same or different and represents hydrogen, C<sub>1-4</sub> alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl-(CH<sub>2</sub>)<sub>n</sub>; and
- each  $R_4$  and  $R_5$  is ~~the same or different and represents hydrogen, C<sub>1-4</sub>-alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl-(CH<sub>2</sub>)<sub>n</sub>~~; wherein:

the phenyl moiety in the group  $R^1$  being unsubstituted or substituted by a single fluorine, chlorine, C<sub>1-2</sub> alkyl, C<sub>1-2</sub> alkoxy, C<sub>1-2</sub> alkylthio, C<sub>1-2</sub> haloalkyl or C<sub>1-2</sub> haloalkoxy substituent;

~~the aryl moieties in the groups  $R^{5'}$ ,  $R^{6'}$  and  $R^{6'''}$  being unsubstituted or substituted by 1,2 or 3 substituents selected from fluorine, chlorine, bromine, iodine, C<sub>1-4</sub>-alkyl, C<sub>2-4</sub>-acyl, hydroxy, C<sub>1-4</sub>-alkoxy, C<sub>1-4</sub>-alkylthio, C<sub>1-6</sub>-haloalkyl, C<sub>1-4</sub>-haloalkoxy, amino,~~

mono(C<sub>1-4</sub>-alkyl)amino, di(C<sub>1-4</sub>-alkyl)amino, nitro, ~~CO<sub>2</sub>R<sup>f</sup>, S(O)<sub>2</sub>R<sup>f</sup> and S(O)<sub>2</sub>NH<sub>2</sub>;~~  
 wherein R<sup>f</sup> represents C<sub>1-2</sub>-alkyl;

~~the heteroaryl moieties in the groups R<sup>5'</sup>, R<sup>6'</sup> and R<sup>6'''</sup> being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C<sub>1-2</sub>-alkyl, C<sub>1-2</sub>-haloalkyl and di(C<sub>1-2</sub>-alkyl)amino;~~


~~the heterocyclyl and carbocyclyl moieties in the R<sup>6'''</sup> group being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C<sub>1-4</sub>-alkyl, C<sub>1-4</sub>-alkoxy, C<sub>1-4</sub>-haloalkyl and nitro;~~

the phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl-(CH<sub>2</sub>)- aryl, heteroaryl and carbocyclyl moieties in the R<sup>f</sup> and R<sup>g</sup> being unsubstituted or substituted by one or two substituents selected from fluorine, chlorine, bromine, C<sub>1-2</sub> alkyl, C<sub>1-2</sub> alkoxy, C<sub>1-2</sub> alkylthio, C<sub>1-2</sub> haloalkyl and nitro; and

~~the aryl, heteroaryl and carbocyclyl moieties in the R<sub>1</sub> and R<sub>2</sub> being unsubstituted or substituted by one or two substituents selected from fluorine, chlorine, bromine, C<sub>1-2</sub> alkyl, C<sub>1-2</sub> alkoxy, C<sub>1-2</sub> alkylthio, C<sub>1-2</sub> haloalkyl and nitro,~~  
 provided that the compound of formula (Ie) is N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-acetamide.

39. (Canceled)

40. (Currently amended) A compound of formula (Ie) or [[a]] pharmaceutically acceptable salts thereof



wherein R<sup>\*</sup> is an aryl group which is unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkylthio, C<sub>1-4</sub> haloalkyl, C<sub>1-4</sub> haloalkoxy and nitro.



41. (Currently amended) A compound according to claim 35, selected from 1,1-Diethyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;  
~~Piperidine-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;~~  
~~Morpholine-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;~~  
~~4-Methyl-piperazine-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;~~  
~~Benzo[b]thiophene-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;~~  
~~Isoxazole-5-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;~~  
~~Benzo[b]thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;~~  
~~N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-methanesulfonamide;~~  
~~Propane-1-sulfonic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;~~  
~~Butane-1-sulfonic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;~~  
~~N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-isonicotinamide;~~  
~~N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide;~~  
~~(S)-2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;~~  
~~(S)-1-(2-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;~~  
~~2-Chloro-4-methanesulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;~~  
~~1-(4-Nitro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;~~  
~~4-Methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;~~  
~~2-Methoxy-4-methylsulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;~~

~~4-Methanesulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;~~

~~N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)terephthalamie acid methyl ester;~~

~~5-Acetyl-2-ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;~~

~~3-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-terephthalamie acid methyl ester;~~

~~2-Methylsulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;~~

~~4-Amino-5-chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;~~

~~4-Methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;~~

~~(S)-2,4,5-Trifluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;~~

~~(S)-5-Acetyl-2-ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;~~

~~2-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-5-sulfamoyl-benzamide;~~

~~1-tert-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;~~

~~1-Cycloheptyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea~~

~~1-Cyclohexyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;~~

~~1-Ethyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;~~

~~1-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;~~

~~4,5-Dimethyl-furan-2-carboxylic acid-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide;~~

~~Piperidine-1-carboxylic acid-(7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;~~

~~Cyclohexanecarboxylic acid-[5-(3-chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;~~

~~Piperidine 1-carboxylic acid [5-(3-chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;~~

~~N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]isonicotinamide;~~

~~Cyclohexanecarboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;~~

~~Piperidine 1-carboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;~~

~~Piperidine 4-carboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;~~

~~Cyclohexanecarboxylic acid (8-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;~~

~~6-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide;~~

~~Pyridine 2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;~~

~~6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;~~

~~1H-Pyrazole 4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;~~

~~6-Dimethylamino-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide;~~

~~2-Ethoxy-naphthalene 1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;~~

~~9-Oxo-9H-fluorene 1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;~~

~~2-Oxo-2,3-dihydro-benzimidazole 1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;~~

~~(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid tert-butyl ester;~~

~~(S)-6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;~~

~~(S) 4,5-Dibromo-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;~~  
~~(S) 3-Methoxy-naphthalene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;~~  
~~(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid-methyl ester;~~  
~~(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid-ethyl ester;~~  
~~(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid-isobutyl ester;~~ or  
~~2-Oxo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-thiophene-2-yl-acetamide;~~  
or a pharmaceutically acceptable salt thereof.

42. (Canceled)
43. (Withdrawn) A pharmaceutical composition comprising a benzodiazepine derivative according to Claim 31, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluant or carrier.
44. (Withdrawn) A composition comprising an optically active isomer of a benzodiazepine derivative according to Claim 31.
45. (Withdrawn) A composition according to claim 43 which is in the form of a tablet, troche, lozenge, aqueous or oily suspension, dispersible powders or granules.
46. (Withdrawn) A process for preparing a benzodiazepine derivative of the formula (I), as defined in claim 1, or a pharmaceutically acceptable salt thereof, which process comprises:
  - (a) reacting 2-amino-benzophenone with bromoacetyl bromide, or an equivalent reagent, followed by ring closure with ammonia;
  - (b) protecting the NH group on the thus obtained compound by reacting with a base and an alkylating agent;
  - (c) reacting the protected intermediate thereby obtained with a base in a suitable solvent, to obtain thereby an oxime intermediate;

- (d) converting the thus obtained oxime intermediate into a corresponding racemic primary amine;
  - (e) carrying out dynamic kinetic resolution on the racemic amine in the presence of a suitable optically active acid and a suitable aldehyde to precipitate a salt of the (S)-amine.
47. (Withdrawn) A process according to claim 46, which further comprises:  
(f) transforming the optically active amine obtained in step (e) into an amide or urea.
48. (Withdrawn) A process according to claim 46 wherein the protecting group introduced in step (b) is 4-methoxy-benzyl.
49. (Withdrawn) A process according to claim 46, wherein the benzodiazepine derivative of the formula (I) is (S)-1-(2-fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea or (S)-4-methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide.
50. (Previously presented) The compound of claim 40, wherein R'\* is a phenyl group which is unsubstituted or substituted by a single fluorine, chlorine, or bromine substituent.
51. (Previously presented) A compound according to claim 40, wherein the compound is (S)-1-(2-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea.
52. (Canceled)
53. (New) A compound according to claim 40, wherein the compound is 1-(4-Nitro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea.
54. (New) A compound according to claim 40, wherein the compound is 1-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea.
55. (New) A compound according to claim 40, wherein the compound is 1,1-Diethyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea.

56. (New) A compound according to claim 40, wherein the compound is 1-tert-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea.

57. (New) A compound according to claim 38, wherein R<sup>1</sup> is phenyl.